Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: A candidate mucosal RSV vaccine

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Remot, Aude ^a   Roux, Xavier ^a,c   Dubuquoy, Catherine ^a   Fix, Jenna ^a   Bouet, Stephan ^b   Moudjou, Mohammed ^a   Eléouët, Jean François ^a   Riffault, Sabine ^a   Petit Camurdan, Agnès ^a  

^a INRA Institut National de la Recherche Agronomique   (France)

^b UMR1313 GÉNÉTIQUE ANIMALE ET BIOLOGIE INTÉGRATIVE   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT NUCLEOPROTEIN N; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; NANOMATERIAL; NUCLEOPROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LUNG INFILTRATE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH2 CELL; TREATMENT RESPONSE; VACCINATION; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CPG ISLAND; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; NEWBORN; PATHOLOGY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CPG ISLANDS; HUMANS; INFANT, NEWBORN; LUNG; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; NUCLEOPROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; TH2 CELLS; VIRAL PROTEINS;

EID: 84861374479     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037722     Document Type: Article

References (55)

1. Chanock R, Finberg L, (1957) Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 66: 291-300.
2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, et al. (2009) The burden of respiratory syncytial virus infection in young children. N Engl J Med 360: 588-598.
3. Tregoning JS, Schwarze J, (2010) Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 23: 74-98.
4. Falsey AR, (2007) Respiratory syncytial virus infection in adults. Semin Respir Crit Care Med 28: 171-181.
5. Pullan CR, Hey EN, (1982) Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. Br Med J (Clin Res Ed) 284: 1665-1669.
6. Perez-Yarza EG, Moreno A, Lazaro P, Mejias A, Ramilo O, (2007) The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J 26: 733-739.
7. Pala P, Bjarnason R, Sigurbergsson F, Metcalfe C, Sigurs N, et al. (2002) Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. Eur Respir J 20: 376-382.
8. Valarcher JF, Taylor G, (2007) Bovine respiratory syncytial virus infection. Vet Res 38: 153-180.
9. van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J, (2007) Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17: 5-34.
10. Graham BS, (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239: 149-166.
11. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE, (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89: 405-421.
12. Prince GA, Curtis SJ, Yim KC, Porter DD, (2001) Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82: 2881-2888.
13. Castilow EM, Varga SM, (2008) Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol 3: 445-454.
14. Zaghouani H, Hoeman CM, Adkins B, (2009) Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol 30: 585-591.
15. PrabhuDas M, Adkins B, Gans H, King C, Levy O, et al. (2011) Challenges in infant immunity: implications for responses to infection and vaccines. Nat Immunol 12: 189-194.
16. Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, et al. (1999) CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol 162: 1611-1617.
17. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL, (1998) CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A 95: 15553-15558.
18. Venter M, Rock M, Puren AJ, Tiemessen CT, Crowe JE Jr, (2003) Respiratory syncytial virus nucleoprotein-specific cytotoxic T-cell epitopes in a South African population of diverse HLA types are conserved in circulating field strains. J Virol 77: 7319-7329.
19. Goulder PJ, Lechner F, Klenerman P, McIntosh K, Walker BD, (2000) Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. J Virol 74: 7694-7697.
20. Boxus M, Tignon M, Roels S, Toussaint JF, Walravens K, et al. (2007) DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge. J Virol 81: 6879-6889.
21. Vaughan K, Rhodes GH, Gershwin LJ, (2005) DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 23: 2928-2942.
22. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, et al. (2009) Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 326: 1279-1283.
23. Tran TL, Castagne N, Bhella D, Varela PF, Bernard J, et al. (2007) The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer. J Gen Virol 88: 196-206.
24. Roux X, Dubuquoy C, Durand G, Tran-Tolla TL, Castagne N, et al. (2008) Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One 3: e1766.
25. Riffault S, Meyer G, Deplanche M, Dubuquoy C, Durand G, et al. (2010) A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus. Vaccine 28: 3722-3734.
26. Cormier SA, You D, Honnegowda S, (2010) The use of a neonatal mouse model to study respiratory syncytial virus infections. Expert Rev Anti Infect Ther 8: 1371-1380.
27. Culley FJ, Pollott J, Openshaw PJ, (2002) Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 196: 1381-1386.
28. Plotnicky H, Siegrist CA, Aubry JP, Bonnefoy JY, Corvaia N, et al. (2003) Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. Vaccine 21: 2651-2660.
29. Siegrist CA, (2001) Neonatal and early life vaccinology. Vaccine 19: 3331-3346.
30. Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA, (1996) Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Eur J Immunol 26: 2666-2670.
31. Dakhama A, Park JW, Taube C, Joetham A, Balhorn A, et al. (2005) The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J Immunol 175: 1876-1883.
32. You D, Becnel D, Wang K, Ripple M, Daly M, et al. (2006) Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. Respir Res 7: 107.
33. Simmons CP, Hussell T, Sparer T, Walzl G, Openshaw P, et al. (2001) Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8+ T cell responses. J Immunol 166: 1106-1113.
34. Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramirez R, et al. (2007) Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 110: 1578-1586.
35. Castilow EM, Legge KL, Varga SM, (2008) Cutting edge: Eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J Immunol 181: 6692-6696.
36. Rosenberg HF, Dyer KD, Domachowske JB, (2009) Respiratory viruses and eosinophils: exploring the connections. Antiviral Res 83: 1-9.
37. Dakhama A, Lee YM, Ohnishi H, Jing X, Balhorn A, et al. (2009) Virus-specific IgE enhances airway responsiveness on reinfection with respiratory syncytial virus in newborn mice. J Allergy Clin Immunol 123: 138-145 e135.
38. VanCott JL, Prada AE, McNeal MM, Stone SC, Basu M, et al. (2006) Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates. J Virol 80: 4949-4961.
39. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, et al. (1996) Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting. Eur J Immunol 26: 1489-1496.
40. Tasker L, Lindsay RW, Clarke BT, Cochrane DW, Hou S, (2008) Infection of mice with respiratory syncytial virus during neonatal life primes for enhanced antibody and T cell responses on secondary challenge. Clin Exp Immunol 153: 277-288.
41. Rose S, Lichtenheld M, Foote MR, Adkins B, (2007) Murine neonatal CD4+ cells are poised for rapid Th2 effector-like function. J Immunol 178: 2667-2678.
42. Lee HH, Hoeman CM, Hardaway JC, Guloglu FB, Ellis JS, et al. (2008) Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. J Exp Med 205: 2269-2280.
43. Roux X, Remot A, Petit-Camurdan A, Nahori MA, Kiefer-Biasizzo H, et al. (2011) Neonatal lung immune responses show a shift of cytokines and transcription factors toward Th2 and a deficit in conventional and plasmacytoid dendritic cells. Eur J Immunol 41: 2852-2861.
44. Martinez X, Li X, Kovarik J, Klein M, Lambert PH, et al. (1999) Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice. Eur J Immunol 29: 3390-3400.
45. Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, et al. (2001) Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 184: 393-399.
46. Miller AL, Bowlin TL, Lukacs NW, (2004) Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis 189: 1419-1430.
47. Culley FJ, Pennycook AM, Tregoning JS, Hussell T, Openshaw PJ, (2006) Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol 80: 4521-4527.
48. Tregoning JS, Pribul PK, Pennycook AM, Hussell T, Wang B, et al. (2010) The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung. PLoS One 5: e9381.
49. Cho JY, Miller M, Baek KJ, Castaneda D, Nayar J, et al. (2001) Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J Allergy Clin Immunol 108: 697-702.
50. Wiley JA, Richert LE, Swain SD, Harmsen A, Barnard DL, et al. (2009) Inducible Bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One 4: e7142.
51. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser K, et al. (2011) The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat Immunol 12: 639-646.
52. Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA, (2009) Intranasal immunization promotes th17 immune responses. J Immunol 183: 6933-6938.
53. Combadiere B, Liard C, (2011) Transcutaneous and intradermal vaccination. Hum Vaccin 7: 811-827.
54. Norton EB, Lawson LB, Freytag LC, Clements JD, (2011) Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant. Clin Vaccine Immunol 18: 546-551.
55. Stevens WW, Kim TS, Pujanauski LM, Hao X, Braciale TJ, (2007) Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods 327: 63-74.